The DOI matches its Crossref record; 37 of the 38 references it cites were found in a registry or an index.
Impairment of caffeine clearance by chronic use of low-dose oestrogen-containing oral contraceptives
Abstract
The effect of chronic (greater than 3 months) administration of low-dose oestrogen-containing (less than 50 micrograms oestrogen) oral contraceptives (OCS) on the pharmacokinetics of caffeine has been examined in a treated females matched with 9 non-smoking, drug-free, healthy control females of similar age, weight and ethnic origin. Each subject received 162 mg caffeine base orally after an overnight fast. OCS subjects had a prolonged elimination half-life of caffeine, (mean 7.88 h vs 5.37 h in the controls). This was the result of marked impairment of the plasma clearance of caffeine (1.05 vs 1.75 ml/min/kg, respectively) with no change in apparent volume of distribution (0.685 in OCS vs 0.7501/kg in the control group). The absorption parameters determined were peak plasma caffeine concentration (3.99 vs 4.09 micrograms/ml) and time to peak concentration after drug administration (1.52 vs 0.79), which was moderately prolonged in OCS users. Thus, caffeine clearance, previously reported to be a specific marker of cytochrome P-448 activity in man, is decreased by chronic OCS use. This suggests that OCS may cause significant impairment of this enzyme activity as assessed in vivo. With chronic caffeine consumption, OCS users are predicted to have an increased steady-state plasma caffeine concentration as compared to non-OCS users.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Factors such as the use of oral contraceptives, the specific phase of the menstrual cycle, and exogenous hormonal status can all influence *CYP1A2*-mediated caffeine metabolism, thereby altering the duration of systemic exposure to caffeine and its primary metabolites—such as paraxanthine and theophylline.”
From Pre-Exercise Caffeine as a Modulator of Exercise-Induced Acute Cardiometabolic Responses: A Narrative Review (2026) · cites this paper as [100]
In the citing paper
“Given that the biological half-life of caffeine may be longer in women than in men, the trajectories of vascular responses, autonomic perturbations, changes in substrate utilization, and residual effects during the recovery phase may differ significantly in women compared to men, even when administered the same dosage [99,100].”
From Pre-Exercise Caffeine as a Modulator of Exercise-Induced Acute Cardiometabolic Responses: A Narrative Review (2026) · cites this paper as [100]
In the citing paper
“Given that the biological half-life of caffeine may be longer in women than in men, the trajectories of vascular responses, autonomic perturbations, changes in substrate utilization, and residual effects during the recovery phase may differ significantly in women compared to men, even when administered the same dosage [99,100].”
From Pre-Exercise Caffeine as a Modulator of Exercise-Induced Acute Cardiometabolic Responses: A Narrative Review (2026) · cites this paper as [100]
In the citing paper
“However, oral contraceptives can prolong caffeine half-life by inhibiting CYP1A2 activity [100], and the menstrual cycle phase may influence thermoregulation, vascular tone, and baseline cardiovascular status.”
From Pre-Exercise Caffeine as a Modulator of Exercise-Induced Acute Cardiometabolic Responses: A Narrative Review (2026) · cites this paper as [100]
In the citing paper
“Oral contraceptives tend to double the half-life of caffeine (59).”
From The Safety of Ingested Caffeine: A Comprehensive Review (2017) · cites this paper as [59]
Citations
Cites
Fundamentals of Clinical Pharmacokinetics
Wagner, J. G. (1975) · Medical Entomology and Zoology · Cited by 1,041
Fundamentals of clinical pharmacokinetics
Crouthamel, W. G. (1976) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600650639 · Cited by 668
Clinical Pharmacokinetics: (First of Two Parts)
Greenblatt, D. J., & Koch-Weser, J. (1975) · New England Journal of Medicine · doi:10.1056/nejm197510022931406 · Cited by 433
The absolute bioavailability of caffeine in man
Blanchard, J., & Sawers, S. J. A. (1983) · European Journal of Clinical Pharmacology · doi:10.1007/bf00613933 · Cited by 378
Effect of smoking on caffeine clearance
Parsons, W. D., & Neims, A. H. (1978) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt197824140 · Cited by 302
Clinical Pharmacokinetics: (Second of Two Parts)
Greenblatt, D. J., & Koch-Weser, J. (1975) · New England Journal of Medicine · doi:10.1056/nejm197511062931905 · Cited by 272
Influence of dietary protein and carbohydrate on antipyrine and theophylline metabolism in man
Kappas, A., Anderson, K. E., Conney, A. H., & Alvares, A. P. (1976) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1976206643 · Cited by 264
Polychlorinated Biphenyls: A New Type of Inducer of Cytochrome P-448 in the Liver
Alvares, A. P., Bickers, D. R., & Kappas, A. (1973) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.70.5.1321 · Cited by 263
Variability in caffeine metabolism
Grant, D. M., Tang, B. K., & Kalow, W. (1983) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1983.80 · Cited by 254
Plasma and salivary pharmacokinetics of caffeine in man
Newton, R., Broughton, L. J., Lind, M. J., Morrison, P. J., Rogers, H. J., & Bradbrook, I. D. (1981) · European Journal of Clinical Pharmacology · doi:10.1007/bf00609587 · Cited by 193
Research works printed but not linked: 1
- Gibaldi M, Perrier D (1975) Pharmacokinetics. Marcel Dekker New York
Cited by
Interindividual Differences in Caffeine Metabolism and Factors Driving Caffeine Consumption
Nehlig, A. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014407 · Cited by 632
“The apparent volume of distribution of caffeine is increased by 60% in obese subjects, but obesity has no effect on caffeine clearance and seems to prolong caffeine half-life by 31%–69% (Abernethy and Todd, 1985; Kamimori et al., 1987).”
BackgroundScientific Opinion on the safety of caffeine
EFSA Panel on Dietetic Products, N. A. A. (. (2015) · EFSA Journal · doi:10.2903/j.efsa.2015.4102 · Cited by 613
“Caffeine has a plasma half-life of about four hours with range of about two to eight hours (Knutti et al., 1981; Abernethy and Todd, 1985; Abernethy et al., 1985; Balogh et al., 1995).”
BackgroundResultThe Safety of Ingested Caffeine: A Comprehensive Review
Temple, J. L., Bernard, C., Lipshultz, S. E., Czachor, J. D., Westphal, J. A., & Mestre, M. A. (2017) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2017.00080 · Cited by 557
“Oral contraceptives tend to double the half-life of caffeine (59).”
BackgroundClinically Significant Pharmacokinetic Interactions Between Dietary Caffeine and Medications
Carrillo, J. A., & Benitez, J. (2000) · Clinical Pharmacokinetics · doi:10.2165/00003088-200039020-00004 · Cited by 364
Caffeine Use in Sports, Pharmacokinetics in Man, and Cellular Mechanisms of Action
Magkos, F., & Kavouras, S. A. (2005) · Critical Reviews in Food Science and Nutrition · doi:10.1080/1040-830491379245 · Cited by 344
Metadata
- Authors
- Abernethy, D. R., & Todd, E. L.
- Affiliations
- Baylor College of Medicine (US)
- Venue
- European Journal of Clinical Pharmacology
- Published
- 1985
- Volume
- 28
- Issue
- 4
- Pages
- 425-428
- ISSN
- 0031-6970 (ISSN-L)
- 1432-1041
- OpenAlex
- W2021943540
- Cited by
- 195
- References
- 38
- Citations by year
- 2026: 10 · 2025: 11 · 2024: 4 · 2023: 3 · 2022: 3 · 2021: 6 · 2020: 19 · 2019: 6 · 2018: 7 · 2017: 5 · 2016: 1 · 2015: 6 · 2014: 7 · 2013: 7 · 2012: 5
- FWCI
- 0.00
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- European Journal of Clinical Pharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- National Institutes of Health (AM 32050)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Health Sciences › Medicine › Pharmacology (medical) › Coffee research and impacts
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Reproductive Health and Contraception
- Keywords
- caffeine, oral contraceptives, estrogen, drug interactions, caffeine clearance, elimination half-life, pharmacokinetics, cytochrome P-448, enzyme inhibition, volume of distribution, absorption
- MeSH terms
- Adult, Caffeine, Contraceptives, Oral, Contraceptives, Oral, Hormonal, Cytochrome P-450 Enzyme System, Drug Interactions, Estrogens, Female, Humans, Liver, Metabolic Clearance Rate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.